Dashboard

Now you are in the subtree of Lecture Notes public knowledge tree. 

[TECH-Idea] CRISPR Gene Therapy

CRISPR gene therapy uses the CRISPR-Cas9 system (and successors: base editing, prime editing) to make precise, targeted changes to DNA inside living patients — correcting disease-causing mutations, silencing pathological genes, or engineering immune cells to fight cancer.

Overview

Casgevy (exa-cel, Vertex/CRISPR Therapeutics) was approved by the FDA in December 2023 for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia — the first CRISPR medicine, and the first functional cure for SCD. One treatment (USD 2.2M) replaces lifetime transfusions and hospitalisations. The pipeline:

  • Cancer immunotherapy: CRISPR-edited CAR-T cells (multiplexed editing removes PD-1, TCR, and MHC to create allogeneic "off-the-shelf" cells); Intellia, Editas, Poseida.
  • Cardiovascular: NTLA-2001 (Intellia) — single in vivo CRISPR injection reduced ATTR amyloidosis protein 87% (Phase I, 2021). VERVE-101 (Verve Therapeutics) — base editing of PCSK9 in liver reduced LDL 55% with a single injection.
  • Neurological: Sarepta's SRP-9001 (AAV gene therapy, not CRISPR) for Duchenne; CRISPR therapies for Huntington's, Friedreich's ataxia in development.
  • Next-gen tools: base editing (Liu lab) enables A→G and C→T conversions without DNA breaks, reducing off-target effects. Prime editing (Liu lab) enables all 12 types of base substitution plus small insertions/deletions. CRISPR-Cas12, Cas13 (RNA targeting) expand the toolkit.

Key Actors

CRISPR Therapeutics (Vertex partner), Intellia Therapeutics, Beam Therapeutics (base editing), Prime Medicine (prime editing), Editas Medicine, Verve Therapeutics, Arbor Biotechnologies, Metagenomi, Sana Biotechnology.

Economic Value

Gene therapy market: USD 10B/year (2023), growing to USD 100B by 2030 (Grand View Research). Sickle cell cure alone: 100,000 US patients × USD 2.2M = USD 220B total addressable US market. Cardiovascular CRISPR (PCSK9): USD 50B+/year if replaces lifetime statins. Cancer immunotherapy: USD 100B+/year. Total CRISPR therapy market: USD 500B+/year by 2035 if multiple indications prove out.

Notes

Nobel Prize in Chemistry 2020 awarded to Jennifer Doudna and Emmanuelle Charpentier. The landmark conversation where the CRISPR-Cas9 editing potential was first conceived occurred in a Puerto Rico café in 2011, described by Charpentier as making her "shiver." The subsequent IP battle between Berkeley (Doudna) and Broad Institute (Zhang) is the most expensive patent dispute in biotechnology history.

Discovery Character

Surprise level: High — CRISPR was discovered as a bacterial immune system, not as a gene-editing tool. Its repurposing as a programmable molecular scalpel was a creative leap that arrived unexpectedly.

Mode: Serendipitous discovery (bacterial immunity, Mojica 2000s), systematic adaptation (Doudna-Charpentier 2012), now systematic clinical development at accelerating pace. The pace of regulatory approval (first approval 11 years after the 2012 paper) was faster than typical biologic timelines.

What This Enables

This node is a current frontier — downstream applications (in vivo aging reversal, germline editing) are ethically contested and too speculative for inclusion here.